HERRON

Main information

  • Trade name:
  • HERRON BABY TEETHING gel tube
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • HERRON BABY TEETHING gel tube
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 59845
  • Last update:
  • 01-12-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

59845

HERRON BABY TEETHING gel tube

ARTG entry for

Medicine Registered

Sponsor

Orion Laboratories Pty Ltd T/A Perrigo Australia

Postal Address

25-29 Delawney Street,BALCATTA, WA, 6021

Australia

ARTG Start Date

20/05/1997

Product category

Medicine

Status

Active

Approval area

Non-Prescription Medicines

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. HERRON BABY TEETHING gel tube

Product Type

Single Medicine Product

Effective date

3/07/2002

Warnings

No Warnings included on Record

Standard Indications

Specific Indications

For the temporary relief of the pain of sore gums.

Additional Product information

Container information

Type

Material

Life Time

Temperature

Closure

Conditions

Tube

Not recorded

2 Years

Store below 30

degrees Celsius

Not recorded

Not recorded

Pack Size/Poison information

Pack Size

Poison Schedule

Not scheduled. Not considered by committee

Components

1. Medicine component

Dosage Form

Route of Administration

Oral Application

Visual Identification

Clear viscous gel characteristic odour and taste.

Active Ingredients

choline salicylate

87 mg/g

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 01.12.2017 at 10:51:49 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

22-2-2019


Orphan designation: Choline tetrathiomolybdate, Treatment of Wilson's disease, 24/01/2013, Positive

Orphan designation: Choline tetrathiomolybdate, Treatment of Wilson's disease, 24/01/2013, Positive

Orphan designation: Choline tetrathiomolybdate, Treatment of Wilson's disease, 24/01/2013, Positive

Europe - EMA - European Medicines Agency

14-2-2019

EU/3/12/1089 (Alexion Europe SAS)

EU/3/12/1089 (Alexion Europe SAS)

EU/3/12/1089 (Active substance: Choline tetrathiomolybdate) - Transfer of orphan designation - Commission Decision (2019)1373 of Thu, 14 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003805

Europe -DG Health and Food Safety